The therapy was designed to reduce the production of mutant alpha-1 antitrypsin protein, which progresses the liver disease.
Takeda and Arrowhead will co-develop the therapy. If approved, Takeda will lead commercialization efforts and split potential profits in a 50/50 structure.
Arrowhead will receive an upfront payment of $300 million, with the potential to earn $740 million in regulatory and commercial milestones.
More articles on surgery centers:
The 3 things facilities should do now to prepare for the 2021 CMS Physician Fee Schedule
6 must-know coding updates in 2020
Blue Cross North Carolina, Wake Forest collaborate on new insurance network
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
